Compare GPK & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPK | CORT |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 9.7B |
| IPO Year | 2007 | 2001 |
| Metric | GPK | CORT |
|---|---|---|
| Price | $11.41 | $114.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $13.08 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 4.5M | 1.2M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | ★ $8,617,000,000.00 | $761,407,000.00 |
| Revenue This Year | N/A | $26.08 |
| Revenue Next Year | $1.15 | $26.98 |
| P/E Ratio | ★ N/A | $1,228.89 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $8.79 | $28.66 |
| 52 Week High | $23.47 | $122.21 |
| Indicator | GPK | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 64.64 |
| Support Level | $9.95 | $76.41 |
| Resistance Level | $12.25 | $122.21 |
| Average True Range (ATR) | 0.46 | 5.13 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 48.02 | 75.23 |
Graphic Packaging Holding Co is a holding company that manufactures and sells a variety of paper-based consumer packaging products through its subsidiaries. The company's reportable segments are; Americas Paperboard Packaging, and International Paperboard Packaging. The majority of the revenue is generated from its Americas Paperboard Packaging segment which includes paperboard packaging sold predominantly to consumer packaged goods (CPG) companies and cups, lids and food containers sold to foodservice companies and quick-service restaurants (QSR) serving the food, beverage, and consumer product markets in the Americas. Geographically, the company operates in Americas, Europe and Asia Pacific regions.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.